We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
An archived look at Bydureon BCise, a former type 2 diabetes treatment discontinued in October 2024. Learn about its dosage, administration, and available alternatives.

It's a significant moment in diabetes care when a medication that was once a treatment option is no longer available. Bydureon BCise, a prescription injection used to manage type 2 diabetes, has been discontinued by its manufacturer, AstraZeneca, as of October 28, 2024. While this news might bring up questions for those who used or were considering Bydureon BCise, it's important to understand that this decision was a business one and not linked to any safety or effectiveness concerns regarding the drug itself. For individuals in India and around the world managing type 2 diabetes, this discontinuation means a shift in treatment strategies. However, the active ingredient in Bydureon BCise, exenatide, is still available in generic forms from other manufacturers, offering a continuity of care for many.
This article serves as an archived look at Bydureon BCise, detailing its intended use, dosage, and administration. It's designed to provide clarity and context for those who may have questions or are seeking information about exenatide-based treatments. Remember, any decisions about your diabetes management should always be made in consultation with your healthcare provider.
Type 2 diabetes is a chronic condition where your body either doesn't produce enough insulin or doesn't use insulin effectively. Insulin is a hormone that helps glucose (sugar) from food get into your cells to be used for energy. When insulin isn't working correctly, glucose builds up in your blood, leading to high blood sugar levels. Over time, this can cause serious health problems affecting the heart, blood vessels, nerves, eyes, and kidneys. Managing type 2 diabetes typically involves a combination of lifestyle changes, such as diet and exercise, and sometimes medication.
Bydureon BCise was a prescription medication specifically developed to help manage type 2 diabetes in adults and certain children. It belonged to a class of drugs called incretin mimetics, which work by mimicking the action of incretin hormones. These hormones are naturally released after eating and help to:
The medication came as a suspension, a specific type of liquid mixture, designed for injection under the skin using a convenient autoinjector pen. This form allowed for once-weekly administration, simplifying the treatment regimen for many patients.
The typical dosage for Bydureon BCise was 2 milligrams (mg) injected subcutaneously (under the skin) once every 7 days. The autoinjector pen contained this single dose in 0.85 milliliters of suspension. It was crucial to use each pen only once.
For those who used Bydureon BCise, administration was designed to be straightforward, often with guidance from a healthcare professional. The injection could be given with or without food. The autoinjector pen made self-administration possible. Before the first use, doctors or nurses would typically demonstrate the correct technique. For detailed, illustrated instructions, patients were advised to refer to the drug's prescribing information.
Bydureon BCise was also approved for use in children aged 10 years and older. The dosage for these younger patients mirrored that of adults: a 2 mg injection administered subcutaneously once every 7 days. However, its safety and effectiveness in children younger than 10 years old were not established.
Missing a dose of any medication can be concerning. With Bydureon BCise, the approach to a missed dose depended on when it was remembered. If the next scheduled dose was more than 3 days away, the missed injection was to be administered immediately. A new dosing schedule, starting from the day the missed dose was taken, would then be followed on a once-every-7-days basis. If unsure about managing a missed dose, consulting a doctor or pharmacist was always recommended. Forgetting doses can be a challenge, and using tools like medication reminders, alarms, or smartphone apps could be very helpful in maintaining a consistent schedule.
Bydureon BCise was generally intended for long-term management of type 2 diabetes. If both the patient and their doctor found the medication to be safe and effective, it was likely to be continued for an extended period.
The discontinuation of Bydureon BCise by AstraZeneca on October 28, 2024, marks the end of its availability. This was a strategic business decision. It's reassuring to know that this action was not prompted by any issues concerning the drug's safety or its ability to manage type 2 diabetes effectively. For patients who relied on Bydureon BCise, the key is to transition to an alternative treatment plan. Your doctor is the best resource to guide you through this process.
While Bydureon BCise is no longer available, the active ingredient, exenatide, remains an option. Generic versions of exenatide injections are available from different pharmaceutical companies. These generic options offer the same therapeutic benefits as Bydureon BCise, providing a viable alternative for many. Your doctor can discuss these options with you, considering your individual health needs and preferences. There are also other classes of diabetes medications available, including oral medications and different types of injectable therapies, such as GLP-1 receptor agonists and insulin, each with its own profile of benefits and potential side effects. A thorough discussion with your healthcare provider will help determine the most suitable treatment path forward.
Managing type 2 diabetes requires ongoing medical supervision. It's essential to maintain regular contact with your doctor. You should consult your doctor if:
Your doctor can provide personalized advice and adjust your treatment plan as needed to ensure optimal health outcomes.
A1: Bydureon BCise was discontinued as a business decision by its manufacturer, AstraZeneca. This was not due to any concerns about the drug's safety or effectiveness.
A2: Yes, exenatide, the active ingredient in Bydureon BCise, is still available in generic forms from other manufacturers. Your doctor can help you find a suitable alternative.
A3: No, Bydureon BCise is no longer available in the United States and likely in other markets as well, following its discontinuation by the manufacturer in October 2024.
A4: You should speak with your doctor immediately to discuss alternative treatment options for your type 2 diabetes. They will help you transition to a new medication or therapy plan.
A5: Yes, there are several other injectable medications for type 2 diabetes, including other GLP-1 receptor agonists and insulin. Your doctor can explain the differences and help you choose the best option for you.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026

Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026